May 7, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and autoimmune diseases, announced today that it has received a notice of allowance from the United States Patent and Trademark Office for exclusively licensed U.S. patent application Ser. No. 11/057.353 containing claims covering the use of thiomolybdates such as oral tetrathiomolybdate (oral TTM) for the treatment of Alzheimer’s disease (AD)... Pipex Pharmaceuticals' Press Release -
Friday, May 9, 2008
Pipex Pharmaceuticals : Notice of Allowance of U.S. Patent for Oral TTM for Alzheimer’s Disease
May 7, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and autoimmune diseases, announced today that it has received a notice of allowance from the United States Patent and Trademark Office for exclusively licensed U.S. patent application Ser. No. 11/057.353 containing claims covering the use of thiomolybdates such as oral tetrathiomolybdate (oral TTM) for the treatment of Alzheimer’s disease (AD)... Pipex Pharmaceuticals' Press Release -
